3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Mesothelioma
3
Neoplasms
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Medical Oncology
1
Lung Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Robotic Surgical Procedures
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
pembrolizumab
1
isophosphamide mustard
1
fludarabine
1
atezolizumab
1
anetumab ravtansine
1
Octreotide
1
Imatinib Mesylate
1
Gemcitabine
1
Fentanyl
1
Cyclophosphamide
1
Cisplatin
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Thymoma
×
anetumab ravtansine
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled